tbuckley/cabot-search huggingface dataset:
THU0581 Three Years of Experience of the Center of Excellence in Patient-Centered Education in Musculoskeletal Care Demonstrates Successful Teaching of the Knowledge and Skills Required for Trainees to Deliver Excellent Musculoskeletal Care
Authors: G.W. Cannon, A.M. Barker, J.P. Beck, J. Berdan, M.J. Battistone
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Musculoskeletal (MSK) complaints are very common in primary and specialty care. Through funding from the Office of Academic Affiliations (OAA) of the Department of Veterans Affairs (VA), we developed a Center of Excellence (COE) for patient-centered MSK care to train residents, associated health trainees, and medical students. <h3>Objectives</h3> To report the participants9 experience and self-assessed competencies during the MSK COE education week and determine the principal diagnoses encountered in the COE interdisciplinary and interprofessional clinics. <h3>Methods</h3> The COE program had two major components. 1) A week of intensive training in MSK care combining didactics, simulations, and clinical experiences (see figure). 2) Two interdisciplinary and interprofessional clinics for evaluating patients with complex MSK disorders and training in joint injections. Trainee competence was assessed by faculty by direct observation in clinical experiences and two-station Objective Structured Clinical exam (OSCE). Trainees report self-assessment of clinical competency before and after COE training. <h3>Results</h3> Since inception three years ago, the COE program has trained 157 trainees: 101 physician trainees from six disciplines and 56 associated health trainees from five disciplines. A review of the first 140 patients seen in the COE MSK interdisciplinary clinic documents a rich clinical training opportunity with an average of 2.4±1.5 complaints per visit, and patients being seen by 2.8±1.2 disciplines. The chief MSK complaint by patients was classified according to the following areas (orthopedics (OrS), rheumatology (RHE), endocrinology (END), and primary care (PC); however, as noted, the vast majority of patients had multiple MSK diagnoses. Trainees reported high satisfaction with the intensive training and COE MSK clinics. Self-assessment of knowledge and skills for several of the key elements evaluated for physician trainees are listed below. Marked increase in self-assessed MSK knowledge and skills were reported in all areas of training and improvement in clinical competence was confirmed on OSCE. <h3>Conclusions</h3> The COE is an interdisciplinary and interprofessional training model that gives trainees a unique experience for learning to manage patients with MSK disease in a rich collaborative setting. <h3>Acknowledgements</h3> This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Academic Affiliations and Office of Specialty Care Services. <h3>Disclosure of Interest</h3> None declared
Bevacizumab in combination with continuous administration of capecitabine plus biweekly oxaliplatin: Preliminary results from the XELOX-AV trial
Authors: M. Echarri, C. Grávalos, J. Cámara, A. Ruiz, L. Garcia-Garcia, M. Hernández, E. Holgado, C. Gómez, G. Garcia, H. Cortes-Funes
Journal: Journal of Clinical Oncology (2008)

15074 Background: XELOX [Oxaliplatin (Oxa) 130 mg/m2 plus Capecitabine (Cape) 1000 mg/m2 bid d1–14, every 3 weeks] with Bevacizumab (Bev) in patients (pts) with mCRC have been previously reported as an active regimen. However, the activity and tolerance of Cape in a biweekly schedule need frequent dose reduction due to toxicity or intolerance. Its use in a continuous schedule administration give more dose density, and have not been well explored in this population of pts yet. We designed a phase II non-randomized trial in combination with Oxa and Bev (biweekly (2/w) (XELOX-AV) to determine the PFS (primary objective) and ORR, metastases resection rate, OS and toxicity (secondary objectives) of this regimen. We present the preliminary data fo the first series of patients Methods: The study was designed to include 32 chemo-naïve pts with measurable, non resectable, histopatologically confirmed colorectal adenocarcinoma, metastatic or locally advanced, ≥ 18 years, ECOG ≤ 2 and adequate organ function. A cycle consists on Cape 600 mg/m2/12 h continuously, Oxa 85 mg/m2 and Bev 5 mg/kg 2/w. Treatment is administered until disease progression, unacceptable toxicity or withdrawal of informed consent. Bev is stopped ≥ 6 w before surgery Results: Fifteen pts are evaluable for toxicity and efficacy. 9 are men. Median age: 57 (39–75). ECOG 0/1:100%. Median number of cycles: 11 (2–21). Tolerance: There was no grade 4 toxicity. Grade 3 adverse events included neurotoxicity (2 pts, after 13 and 14 cycles respectively), hand-foot syndrome (3 pts) and diarrhea (3 pts). Specific adverse events related to Bev were uncommon: hypertension (all grade 1, 3 pts) and hemorrhage (all grade 1, 4 pts). GI perforations have not been reported. Efficacy: 8 pts (53.3%) achieved response (1 RC; 7 RP), 5 (33.3%) stabilization, (86.6% control disease rate). 2 pts underwent advanced/metastatic disease resection. Data of PFS and OS will be presented at the meeting. Conclusions: The combination of Bevacizumab and Oxaliplatin in a biweekly administration in combination with continuos administtation of Capecitabine seems to be well tolerated and has a promising activity. The study is ongoing. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Roche Roche Roche
Adapting ASCO and NCCN guidelines in institutional antiemetic guidelines benefits patients receiving chemotherapy
Authors: E. Moreno, M. Majem, X. Gonzalez, A. Feliu, M. Comillas, N. Calvo, I. Gich, P. Modamio, M. Mangues, A. Barnadas Molins
Journal: Journal of Clinical Oncology (2008)

20508 Background: The primary endpoint of the present study was to determine the impact of adapting ASCO and NCCN guidelines for antiemetics (AE) in our institutional antiemetic guidelines. Methods: The emetic risk of chemotherapy regimens was calculated using the Hesketh classification. AE guidelines were adapted and approved by a multidisciplinary team and the Drugs and Therapeutics Committee. We have compared 2 groups: patients receiving the new adapted institutional AE with those receiving non-established antiemetic treatment. Patients recorded episodes of nausea and vomiting in a diary the day of chemotherapy administration and the following 4 days. Patients also recorded rescue antiemetic medications. Patients completed the Functional Living Index- Emesis (FLIE) questionnaire at baseline and on day 6. The FLIE total scores >108 was defined as ‘no impact on daily functional‘. The main updates of the new adapted AE guidelines included the addition of aprepitant in cisplatin-based schedules, granisetron dose of 1 mg instead of 3 mg or ondansetron and dexametasone dose based on the emetic potential of each chemotherapy protocol. A delayed antiemetic protocol was recommended for each chemotherapy protocol. Results: From February 2007 to August 2007 225 consecutive patients were prospectively included in the study, 119 patients before the implementation of new AE guidelines and 106 patients after. Patients receiving the new AE guidelines achieved a trend for more complete response (defined as no nausea, no vomiting and no AE rescue): 52% vs 66.7% (p=0.065). In the cisplatin-based group, patients receiving the new AE guidelines obtained a statistically significant benefit with the new protocol (47.6% vs 73.3 % [p=0.017]), and less patients presented a reduction in the FLIE score below 108 (42 % vs 24% [p=0.142]). Conclusions: Implementation of revised AE guidelines provides a better control of CINV with higher complete response rate, especially in patients receiving cisplatin-based schedules. No significant financial relationships to disclose.
Grasp-to-retract modification of the tulip-bundle technique in forward and retroflexed position for difficult hemostatic therapy in the sigmoid colon
Authors: Rolando Pinho, Joana Silva, Ana Ponte, Jaime Rodrigues, Iolanda Ribeiro, Maria Lucas, João Carvalho
Journal: Endoscopy (2015)

A 60-year-old woman with no relevant medical history underwent endoscopic mucosal resection (EMR) of a 7-cm 0-Is lesion in the distal sigmoid colon. A solution of saline, indigo carmine, and 1/100 000 adrenaline was injected into the submucosa, and piecemeal snare resection was performed ([Fig. 1]). Persistent oozing occurred during EMR and was partially controlled by subsequent submucosal injections and resections. After complete resection, a 4 × 4 cm mucosal defect over a colonic fold could be seen, with diffuse oozing but no visible vessels.
A new complication of permanent indwelling central venous catheters using high-dose fluorouracil and leucovorin.
Authors: B Ardalan, M R Flores
Journal: Journal of Clinical Oncology (1993)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1993.11.2.384 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8426219 A new complication of permanent indwelling central venous catheters using high-dose fluorouracil and leucovorin. B ArdalanxB ArdalanSearch for articles by this author , M R FloresxM R FloresSearch for articles by this author https://doi.org/10.1200/JCO.1993.11.2.384 PDF "A new complication of permanent indwelling central venous catheters using high-dose fluorouracil and leucovorin.." Journal of Clinical Oncology, 11(2), p. 384© 1993 by American Society of Clinical Oncology
SAT0648-HPR Development of a Patient Education Program for New Mothers with Rheumatic Disease
Authors: T. Moksnes, I.R. Nilssen
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Patient education (PE) is “a planned, interactive process between patients and health professionals, aimed at supporting and enabling patients to manage their life with arthritis and optimizing their health and well-being”. PE is considered an integral part of the management of inflammatory arthritis (IA)(1). As the preliminary recommendations from the EULAR task force says: All people with IA should have access to and be offered PE throughout the course of their disease including as a minimum, at diagnosis, at pharmacological treatment change and when required by patient9s physical or psychological condition. When a woman with a rheumatic disease becomes a mother, it often includes a lot of new challenges in coping with both her chronic disease and her new role as a mother. <h3>Objectives</h3> To develop a PE program adapted to this group of patients and their needs in a new phase of life. The purpose is to support and enable the patients to cope with the new challenges being a new mother when having a rheumatic disease, and facilitate networking with other women in similar life situations. <h3>Methods</h3> 6 participants with different rheumatic diseases who had recently given birth were recruited from the rheumatology unit at St. Olavs Hospital. The group sessions were led by a midwife who is specialized in rheumatology. 4 meetings were held with about 3 week9s interval. Meetings were held in a suitable meeting room at St. Olavs Hospital. Each session lasted about two hours. The meeting had the following themes: 1. Everyday life, practical challenges and questions with an occupational therapist. 2. Exercise and diet with an exercise instructor and nurse. 3. Relationships and sexuality with midwife. 4. Laws and rights with a social worker. 5. A follow-up meeting is scheduled about 4 months after the group ended. To quality assure and evaluate the project we conducted a focus group interview at the end of the fourth session. <h3>Results</h3> The main results from the interview, and what the group participants identified as most important for them when were: “meet people in the same situation and share experiences”, “a place where you can discuss illness and be met with understanding”, “nice with meetings during daytime also with the baby included”, “they wanted more meetings, because they felt it was easier to discuss difficult themes when they had become better acquainted”, “they suggested that also their partners could have benefited information about their conditions from health professionals”. <h3>Conclusions</h3> The participants from the first group expressed that they felt the group had been beneficial and useful. We will continue to further develop and evaluate the concept. <h3>References</h3> Task Force definition of patient education, EULAR recommendations/points to consider for patient education of people with inflammatory arthritis. Amsterdam, July 2013. Stamm T, Hill J. <h3>Disclosure of Interest</h3> None declared
Effects of Meals of Different Fats on Blood Coagulation
Authors: ANCEL KEYS, RATKO BUZINA, FRANCISCO GRANDE, JOSEPH T. ANDERSON
Journal: Circulation (1957)

Previous work has shown that a high-fat meal produces an increased coagulability of the blood. This fact is of interest in view of the effects of dietary fat on the serum cholesterol and its association with coronary disease. Since fats containing large amounts of unsaturated fatty acid tend to reduce the serum cholesterol rather than increase it, it is important to examine the effects of fats with different fatty acid composition on blood coagulation. Comparisons are presented of the effect on blood coagulability of feeding butterfat, corn oil, hydrogenated coconut oil, and a marine fish oil.
Reliability of best-estimate diagnosis in genetic linkage studies of major psychoses: results from the Quebec pedigree studies
Authors: M Maziade, M A Roy, J P Fournier, D Cliche, C Mérette, C Caron, Y Garneau, N Montgrain, C Shriqui, C Dion
Journal: American Journal of Psychiatry (1992)

Diagnostic classification and reliability are critical in genetic linkage studies of schizophrenia and bipolar disorder. To establish an optimal diagnostic procedure, the authors drew 13 methodological elements from 38 major linkage studies and workshop reports. They determined reliability for a consensus best-estimate diagnostic method based on these 13 features.Each of 59 subjects from several large multiplex pedigrees, densely affected by either schizophrenia or bipolar disorder, received a best-estimate diagnosis from unblind diagnosticians in the field and also from a panel of four research psychiatrists who were blind to the proband's and relatives' clinical status. The best estimate was based on personal diagnostic interviews, all available medical records, and family history data.The diagnostic concordance between the field team and the blind psychiatric board yielded 78% to 90% agreement for the whole sample (kappa = 0.83-0.88) and 71% to 87% agreement for the subjects given field diagnoses (kappa = 0.76-0.83). The diagnoses made by the unblind field diagnosticians were biased toward a greater severity (or certainty) level in the diagnostic hierarchy (schizophrenic or bipolar) and more consistency with the most prevalent diagnosis affecting the pedigree.Since several previous linkage studies used diagnoses made by diagnosticians who were not blind to the status of the probands and the relatives or did not use a consensus best-estimate diagnosis, further reliability studies of different aspects of the best-estimate method and of its effect on linkage studies are needed. Such research is imperative given the serious impact of diagnostic misclassifications on genetic linkage results.
A Surface Antigen Associated With Hodgkin's Disease: Brief Communication 2
Authors: Roger Favre, Yves Carcassonne, Georges Meyer
Journal: JNCI Journal of the National Cancer Institute (1977)

We used an indirect immunofluorescence technique to detect a surface antigen that may be associated with Hodgkin's disease (HD). A heteroantiserum raised in a rabbit given an injection of cells obtained from an HD lymph node (Stage I, classification of Lukes and Butler) allowed us to detect an antigen on the surfaces of HD-derived cells in 25 of 27 instances. Benign and malignant non-HD-type lesions (both lymph node and spleen) did not have this antigen. The nature of this antigen and the type of cells bearing it are unknown.
In Defense of Off-label Prescribing—Reply
Authors: Tewodros Eguale, Aman Verma, Robyn Tamblyn
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
A Preliminary Report on the Effect of Thyroid Analogues in Neoplastic Diseases in Man&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Morton, Donald L., Petrakis, Nicholas L., Wood, David A.
Journal: JNCI Journal of the National Cancer Institute (1959)

Journal Article A Preliminary Report on the Effect of Thyroid Analogues in Neoplastic Diseases in Man Get access Donald L. Morton, Donald L. Morton Cancer Research Institute, and the Departments of Preventive Medicine and Medicine, University of California School of Medicine, San Francisco, California Search for other works by this author on: Oxford Academic PubMed Google Scholar Nicholas L. Petrakis, Nicholas L. Petrakis Cancer Research Institute, and the Departments of Preventive Medicine and Medicine, University of California School of Medicine, San Francisco, California Search for other works by this author on: Oxford Academic PubMed Google Scholar David A. Wood David A. Wood Cancer Research Institute, and the Departments of Preventive Medicine and Medicine, University of California School of Medicine, San Francisco, California Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 22, Issue 3, March 1959, Pages 543–550, https://doi.org/10.1093/jnci/22.3.543 Published: 01 March 1959 Article history Received: 17 September 1958 Published: 01 March 1959
Biomimetic Acoustically-Responsive Vesicles for Theranostic Applications
Authors: Chen-Chan Hsieh, Shih-Tsung Kang, Yee-Hsien Lin, Yi-Ju Ho, Chung-Hsin Wang, Chih-Kuang Yeh, Chien-Wen Chang
Journal: Theranostics (2015)

In recent years, biomimetic cell membrane-derived particles have emerged as a new class of drug delivery system with advantages of biocompatibility, ease of isolation and long circulation profile.Here we report the development and potential theranostic applications of a new biomimetic acoustically-responsive droplet system derived from mammalian red blood cell membrane (RBCM).We hypothesized that drug-loaded RBCM droplets (RBCMDs) would undergo a transition from liquid (droplets) to gas (bubbles) upon high intensity focused ultrasound (HIFU) insonation, resulting in on-demand drug release.The generated microbubbles could also serve as a contrast agent to enhance ultrasound imaging.As-synthesized RBCMDs exhibited uniform size, good dispersity and preservation of RBCM-associated proteins that prevented uptake by macrophages.Camptothecin (CPT), an anti-cancer drug, was successfully loaded in the RBCMDs with a loading efficiency of 2-3% and an encapsulation efficiency of 62-97%.A short (3 min) exposure to HIFU irradiation triggered release of CPT from the RBCMDs and the physical explosion of droplets damaged nearby cancer cells resulting in significant cell death.In addition, the acoustically vaporized RBCMDs significantly increased the ultrasound echo signal to 30 dB.Lastly, we demonstrated that RBCMDs could be acoustically vaporized in vivo in target tissues, and enhancing ultrasound imaging.Taken together, we have developed a new class of naturally derived RBCMDs which show great potential for future application in remotely triggered drug delivery and ultrasound imaging enhancement.
MicroRNA in alcoholic hepatitis: implications for pathophysiology and treatment
Authors: Felix Stickel, Laurent Dubuquoy
Journal: Gut (2016)

Alcoholic hepatitis alcoholic hepatitis (AH) represents a necroinflammatory complication of alcoholic liver disease, which affects a relatively small but considerable fraction of heavy drinkers with various degrees of underlying alcoholic liver damage. The true incidence of alcoholic hepatitis (AH) is unclear, but is found in around 20% of those with available liver histology, and estimated in approximately 10%–35% of alcoholics hospitalised for decompensating liver disease.1 Severe alcoholic hepatitis (AH) severe alcoholic hepatitis (sAH) has a grave prognosis with a 1-month mortality rate of up to 50%, a figure assessed for patients with a discriminant function score of ≥32 in the initial treatment trial by Maddrey and coworkers.2 Since that time, advances in intensive care medicine, response-guided treatment of selected patients with corticosteroids and improved management of infectious complications contributed to a slightly better outcome of patients with severe alcoholic hepatitis (sAH).3 Although randomised clinical trials have explored several options, effective medical treatments that improve the underlying inflammatory process are still restricted to corticosteroids to which only 50% of patients with severe alcoholic hepatitis (sAH) respond adequately.

The pathogenesis of severe alcoholic hepatitis (sAH) involves cytokine-mediated necroinflammation of the liver parenchyma, consecutive hepatocyte damage and cholestasis in the context of a systemic inflammatory response syndrome. Yet, the entire pathophysiology is still only incompletely understood and likely encompasses hitherto unknown mechanisms that could be crucial and potentially exploitable for therapeutic intervention. Hence, studies that pursue novel hypotheses to explore new therapeutic targets are of particular interest. Among the manifold potential mechanisms is that of microRNAs (miRNA) in human diseases, including liver diseases. miRNAs are highly conserved small non-coding RNA molecules that is composed of 18–25 nucleotides involved in epigenetic regulation of numerous target genes either at the posttranscriptional level or transcriptionally via targeting promoter …
Case 16-1986
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, Betty U. McNeely, Louis R. Caplan, Edward P. Richardson
Journal: New England Journal of Medicine (1986)

Presentation of CaseA 68-year-old right-handed woman was admitted to the hospital because of a progressive speech disorder.She was well until eight months earlier, when she gradually began to experience difficulty in expressing herself. She groped for words, sometimes used the wrong word, and sputtered or stammered in speaking. She had difficulty in recalling persons' names; her memory was good in other respects, and she remained capable of organizing her housework, balancing her checkbook, and playing bridge, but less rapidly than in the past. She was always a slow reader and had struggled to get through college. Her spelling . . .